These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 26345140)
1. Molecular targets in arthritis and recent trends in nanotherapy. Roy K; Kanwar RK; Kanwar JR Int J Nanomedicine; 2015; 10():5407-20. PubMed ID: 26345140 [TBL] [Abstract][Full Text] [Related]
2. The bispecific antibody aimed at the vicious circle of IL-1β and IL-17A, is beneficial for the collagen-induced rheumatoid arthritis of mice through NF-κB signaling pathway. Wu Q; Wang Y; Wang Q; Yu D; Wang Y; Song L; Liu Z; Ye X; Xu P; Cao H; Li D; Ren G Immunol Lett; 2016 Nov; 179():68-79. PubMed ID: 27616043 [TBL] [Abstract][Full Text] [Related]
3. A recombinant IgG-like bispecific antibody acting as interleukin-1β and interleukin-17A inhibitor exhibits a promising efficacy for rheumatoid arthritis. Wang Y; Wu Q; Liu Z; Guo X; Zhou L; Wang Y; Song L; Wang N; Zheng Q; Wang W; Ren G; Li D Biomed Pharmacother; 2017 May; 89():426-437. PubMed ID: 28249243 [TBL] [Abstract][Full Text] [Related]
4. Perspectives From Masters in Rheumatology and Autoimmunity: Can We Get Closer to a Cure for Rheumatoid Arthritis? Feldmann M; Maini RN Arthritis Rheumatol; 2015 Sep; 67(9):2283-91. PubMed ID: 26138641 [No Abstract] [Full Text] [Related]
5. Fibroblast-like synoviocytes-dependent effector molecules as a critical mediator for rheumatoid arthritis: Current status and future directions. Ganesan R; Rasool M Int Rev Immunol; 2017 Jan; 36(1):20-30. PubMed ID: 28102734 [TBL] [Abstract][Full Text] [Related]
6. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Pérez-Herrero E; Fernández-Medarde A Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885 [TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Herman S; Krönke G; Schett G Trends Mol Med; 2008 Jun; 14(6):245-53. PubMed ID: 18468489 [TBL] [Abstract][Full Text] [Related]
8. New cytokine targets in inflammatory rheumatic diseases. Connell L; McInnes IB Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):865-78. PubMed ID: 16980211 [TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model. Zhang Y; Ren G; Guo M; Ye X; Zhao J; Xu L; Qi J; Kan F; Liu M; Li D Int Immunopharmacol; 2013 Feb; 15(2):199-205. PubMed ID: 23280345 [TBL] [Abstract][Full Text] [Related]
10. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. Varshosaz J; Farzan M World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. Ruscitti P; Cipriani P; Cantarini L; Liakouli V; Vitale A; Carubbi F; Berardicurti O; Galeazzi M; Valenti M; Giacomelli R J Med Case Rep; 2015 Jun; 9():123. PubMed ID: 26033326 [TBL] [Abstract][Full Text] [Related]
12. Colloidal gold: a novel nanoparticle for targeted cancer therapeutics. Powell AC; Paciotti GF; Libutti SK Methods Mol Biol; 2010; 624():375-84. PubMed ID: 20217609 [TBL] [Abstract][Full Text] [Related]
13. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Koenders MI; Joosten LA; van den Berg WB Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii29-33. PubMed ID: 17038468 [TBL] [Abstract][Full Text] [Related]
14. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Shapira A; Livney YD; Broxterman HJ; Assaraf YG Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184 [TBL] [Abstract][Full Text] [Related]
16. Nanomedicine applications in the treatment of breast cancer: current state of the art. Wu D; Si M; Xue HY; Wong HL Int J Nanomedicine; 2017; 12():5879-5892. PubMed ID: 28860754 [TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Fischer JA; Hueber AJ; Wilson S; Galm M; Baum W; Kitson C; Auer J; Lorenz SH; Moelleken J; Bader M; Tissot AC; Tan SL; Seeber S; Schett G Arthritis Rheumatol; 2015 Jan; 67(1):51-62. PubMed ID: 25303306 [TBL] [Abstract][Full Text] [Related]
18. Comparison of anti-rheumatic effects of local RNAi-based therapy in collagen induced arthritis rats using various cytokine genes as molecular targets. Inoue A; Takahashi KA; Mazda O; Arai Y; Saito M; Kishida T; Shin-Ya M; Morihara T; Tonomura H; Sakao K; Imanishi J; Kubo T Mod Rheumatol; 2009; 19(2):125-33. PubMed ID: 19030778 [TBL] [Abstract][Full Text] [Related]
19. Role of integrated cancer nanomedicine in overcoming drug resistance. Iyer AK; Singh A; Ganta S; Amiji MM Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506 [TBL] [Abstract][Full Text] [Related]
20. Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model. Plater-Zyberk C; Joosten LA; Helsen MM; Koenders MI; Baeuerle PA; van den Berg WB Ann Rheum Dis; 2009 May; 68(5):721-8. PubMed ID: 18495731 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]